Andrade 2012.

Methods	Design: parallel (2 arms) Country: Brazil Multicenter: unclear International: no Follow‐up period: unknown Treatment duration: 4 weeks
Participants	Randomised: 39 Rosuvastatin: 23 Placebo: 16 Trial authors did not report information on: age, gender, inclusion or exclusion criteria, or New York Heart Association stage.
Interventions	Rosuvastatin: 20 mg/day. Manufacturer: not given. Placebo (physical and chemical properties): not reported. Treatment duration: four weeks. Cointervention: not given.
Outcomes	Serum markers of inflammation (C Reactive Protein) Quality of life Trial authors did not classify their outcomes as primary or secondary.
Notes	All information was gathered from an abstract. Date of trial: not reported. Trial register number: not reported. Sample size estimation a priori: not reported. Sponsor: not reported. Role of sponsor: does not apply. We sent an e‐mail to the trial author on 23 January 2015.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote "... we randomized..." (Page 90). Insufficient information to permit judgment of 'low risk' or 'high risk'
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote "...double‐blind, placebo‐controlled..." (page 90) Insufficient information to permit judgement of 'low risk' or 'high risk'
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote "...double‐blind, placebo‐controlled..." (page 90) Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Selective reporting (reporting bias)	High risk	The study report failed to include results for a key outcome that would be expected to have been reported for such a study
Other bias	High risk	Bias in the presentation of the data.